150 related articles for article (PubMed ID: 28243577)
1. Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients.
Giugliani R; Harmatz P; Jones SA; Mendelsohn NJ; Vellodi A; Qiu Y; Hendriksz CJ; Vijayaraghavan S; Whiteman DA; Pano A
Mol Genet Metab Rep; 2017 Sep; 12():2-7. PubMed ID: 28243577
[TBL] [Abstract][Full Text] [Related]
2. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
Pano A; Barbier AJ; Bielefeld B; Whiteman DA; Amato DA
Orphanet J Rare Dis; 2015 Apr; 10():50. PubMed ID: 25902842
[TBL] [Abstract][Full Text] [Related]
4. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
Burton BK; Whiteman DA;
Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
[TBL] [Abstract][Full Text] [Related]
6. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report.
Kim S; Whitley CB; Jarnes Utz JR
Mol Genet Metab; 2017 Sep; 122(1-2):92-99. PubMed ID: 28610913
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).
Muenzer J; Giugliani R; Scarpa M; Tylki-Szymańska A; Jego V; Beck M
Orphanet J Rare Dis; 2017 Oct; 12(1):161. PubMed ID: 28974237
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.
Muenzer J; Burton BK; Harmatz P; Gutiérrez-Solana LG; Ruiz-Garcia M; Jones SA; Guffon N; Inbar-Feigenberg M; Bratkovic D; Hale M; Wu Y; Yee KS; Whiteman DAH; Alexanderian D;
Mol Genet Metab; 2022; 137(1-2):127-139. PubMed ID: 36027721
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy.
Giugliani R; Hwu WL; Tylki-Szymanska A; Whiteman DA; Pano A
Genet Med; 2014 Jun; 16(6):435-41. PubMed ID: 24202085
[TBL] [Abstract][Full Text] [Related]
13. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
[TBL] [Abstract][Full Text] [Related]
14. Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 study.
Seo JH; Kosuga M; Hamazaki T; Shintaku H; Okuyama T
Mol Genet Metab; 2023 Dec; 140(4):107709. PubMed ID: 37922836
[TBL] [Abstract][Full Text] [Related]
15. Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II.
Muenzer J; Vijayaraghavan S; Stein M; Kearney S; Wu Y; Alexanderian D
Genet Med; 2022 Jul; 24(7):1437-1448. PubMed ID: 35588317
[TBL] [Abstract][Full Text] [Related]
16. A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT.
Yee KS; Chirila C; Davenport E; Mladsi D; Barnett C; Kronenberger WG
Orphanet J Rare Dis; 2023 Nov; 18(1):343. PubMed ID: 37915038
[TBL] [Abstract][Full Text] [Related]
17. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
[TBL] [Abstract][Full Text] [Related]
18. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).
Burton BK; Jego V; Mikl J; Jones SA
J Inherit Metab Dis; 2017 Nov; 40(6):867-874. PubMed ID: 28887757
[TBL] [Abstract][Full Text] [Related]
19. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
[TBL] [Abstract][Full Text] [Related]
20. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).
Muenzer J; Wraith JE; Beck M; Giugliani R; Harmatz P; Eng CM; Vellodi A; Martin R; Ramaswami U; Gucsavas-Calikoglu M; Vijayaraghavan S; Wendt S; Puga AC; Ulbrich B; Shinawi M; Cleary M; Piper D; Conway AM; Kimura A
Genet Med; 2006 Aug; 8(8):465-73. PubMed ID: 16912578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
